key: cord-0789643-7r69hwzy
authors: Ke, Shanlin; Weiss, Scott T.; Liu, Yang-Yu
title: Dissecting the Role of the Human Microbiome in COVID-19 via Metagenome-assembled Genomes
date: 2022-03-10
journal: bioRxiv
DOI: 10.1101/2022.03.09.483704
sha: 2618f30a8542e08f4d1181fc5be256c8b1d50f91
doc_id: 789643
cord_uid: 7r69hwzy

Coronavirus disease 2019 (COVID-19), primarily a respiratory disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is often accompanied by gastrointestinal symptoms. However, little is known about the relation between the human microbiome and COVID-19, largely due to the fact that previous studies fail to provide high taxonomic resolution to identify microbes that likely interact with SARS-CoV-2 infection. Here we used whole-metagenome shotgun sequencing data together with assembly and binning strategies to reconstruct metagenome-assembled genomes (MAGs) from a total of 514 nasopharyngeal and fecal samples of patients with COVID-19 and controls. We reconstructed a total of 11,584 medium-and high-quality microbial MAGs and obtained 5,403 non-redundant MAGs (nrMAGs) with strain-level resolution. We found that, thanks to the high taxonomic resolution of nrMAGs, the gut microbiome signatures can accurately distinguish COVID-19 cases from healthy controls and predict the progression of COVID-19. Moreover, we identified a set of nrMAGs with a putative causal role in the clinical manifestations of COVID-19 and revealed their functional pathways that potentially interact with SARS-CoV-2 infection. The presented results highlight the importance of incorporating the human gut microbiome in our understanding of SARS-CoV-2 infection and disease progression. The genomic content of nrMAGs presented here has the potential to inform microbiome-based therapeutic developments for COVID-19 progression and post-COVID conditions.

Coronavirus disease 2019 , primarily a respiratory disease caused by infection with 13

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is often accompanied by 14 gastrointestinal symptoms. However, little is known about the relation between the human 15 microbiome and COVID-19, largely due to the fact that previous studies fail to provide high 16 taxonomic resolution to identify microbes that likely interact with SARS-CoV-2 infection. Here 17 we used whole-metagenome shotgun sequencing data together with assembly and binning 18 strategies to reconstruct metagenome-assembled genomes (MAGs) from a total of 514 19 nasopharyngeal and fecal samples of patients with COVID-19 and controls. We reconstructed a 20 total of 11,584 medium-and high-quality microbial MAGs and obtained 5,403 non-redundant 21

MAGs (nrMAGs) with strain-level resolution. We found that, thanks to the high taxonomic 22 resolution of nrMAGs, the gut microbiome signatures can accurately distinguish COVID-19 23 cases from healthy controls and predict the progression of COVID-19. Moreover, we identified a 24 set of nrMAGs with a putative causal role in the clinical manifestations of revealed their functional pathways that potentially interact with SARS-CoV-2 infection. The 26

presented results highlight the importance of incorporating the human gut microbiome in our 27

understanding of SARS-CoV-2 infection and disease progression. The genomic content of 28 nrMAGs presented here has the potential to inform microbiome-based therapeutic developments 29

for COVID-19 progression and post-COVID conditions. 30 31  32  33  34  35  36  37  38  39  40 Introduction 41 The ongoing pandemic of coronavirus disease 2019 , a respiratory disease caused by 42 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected billions of people 43 world-wide. A broad range of clinical manifestations of COVID-19 has been reported, including 44 asymptomatic or mild disease with cough and fever to severe pneumonia with multiple organ 45 failure and acute respiratory distress syndrome (ARDS) leading to death 1 . Existing studies found 46 that a large proportion of COVID-19 patients had at least one gastrointestinal (GI) symptom 2-5 , 47 such as diarrhea, vomiting, or belly pain. Moreover, it has been reported that, among 73 SARS-48

CoV-2-infected hospitalized patients in China, 53.4% of patients tested positive for SARS-CoV-49 2 in their stool samples ranging from day 1 to 12 post infection 6 . Importantly, in more than 20% 50 of infected patients, their fecal samples remained positive for the virus even after the respiratory 51 and/or sputum samples exhibited no detectable virus 6 . In some cases, the viral load in feces is 52 even higher than that in pharyngeal swabs 3 . All these results suggest that the GI tract might be an 53 important extra-pulmonary site for SARS-CoV-2 infection. Currently, the role of angiotensin-54

converting enzyme 2 (ACE2) in the invasion of host cells by SARS-CoV-2 via its spike protein 55 is well-established 7 , and ACE2 is also highly expressed in the small intestine and colon 4,8 . 56 Therefore, the prolonged presence of large amounts of fecal SARS-CoV-2 RNA virus is unlikely 57 to be explained by the swallowing of virus particles replicated in the throat but rather suggests 58 enteric infection with SARS-CoV-2. 59 60

The human GI tract is the largest immune organ in the body and plays a critical role in the 61 immune response to pathogenic infection or commensal intrusion 9 . Trillions of microbes live 62 inside the GI tract. Those microbes and their genes, collectively known as the human gut 63 microbiome, modulate host immunity 10 . To date, several studies, based on 16S rRNA gene 64 sequencing, have demonstrated that the human upper respiratory and gut microbiome are broadly 65 altered in patients with . Although 16S rRNA gene sequencing provides valuable 66 insights into the general characteristics of the human microbiota, it does not offer the taxonomic 67 resolution needed to capture sufficient sequence variation to discriminate between closely related 68 taxa 16 . Other studies, based on whole-metagenome shotgun (WMS) sequencing, explored the 69 links between the human microbiome and SARS-CoV-2 infection by mapping short 70 metagenomic reads to reference genome databases [17] [18] [19] [20] [21] . Despite the fact that the analysis of WMS 71 sequencing data provides more information than 16S rRNA gene sequencing data analysis, 72

existing studies based on reference genome databases are subject to the limitations and biases of 73 those databases and unable to characterize microbes that do not have closely related culture 74

representatives. In fact, an estimated 40-50% of human gut species lack a reference genome 22,23 . 75 This may result in a strong null bias in characterizing the gut microbial community. 76 77

An alternative strategy to analyze WMS sequencing data is to reconstruct metagenome-78 assembled genomes (MAGs) through de novo assembly and binning 24 . One key advantage of this 79 strategy is that it allows recovery of genomes for microorganisms that have yet to be isolated and 80 cultured and hence are absent from the current reference genome databases. This strategy has 81 been adopted in several studies to provide genomic insights into microbial populations that are 82 critical to human health and disease 25, 26 . In this study, we applied state-of-the-art metagenome 83 assembly and binning strategies to reconstruct microbial population genomes directly from 84 microbiome samples of COVID-19 patients and controls (Fig. 1) . Our major goals were to 85 construct a COVID-19 related metagenomic genome catalog to identify novel taxa and strain-86 level differences that are likely related to the clinical manifestations of SARS-COV-2 infection. 87

Our results demonstrate the association of the human microbiome and SARS-COV-2 infection at 88

an unprecedentedly high level of taxonomic resolution. More importantly, our study provides a 89 unique resource to directly investigate the genomic content of COVID-19 relevant microbial 90 strains and sheds light on more targeted follow-up studies. 91 92

COVID-19 related metagenomic data sets 94

To examine the relation between the human microbiome and COVID-19 via MAGs, we first 95 gathered WMS sequencing data from the COVID-19 related human microbiome studies 96

(publicly available as of August 2021). We collected the raw WMS sequencing data of 514 97 microbiome samples (n=359 individuals) from six publicly available datasets ( Fig.1a and Table  98 1) with different technical settings (e.g., sequencing platform and sequencing depth), including 99 nasopharyngeal (n=96) and fecal microbiome (n=418) relatively higher rates of total MAGs and nrMAGs than COVID-19 microbiome samples as 120

In the data set from Yeoh et al. 18 , the gut microbiome samples from those patients with COVID-162  19 were collected before and after their nasopharyngeal aspirates or swabs tested negative for  163  SARS-CoV-2 via RT-qPCR. Furthermore, patients with COVID-19 were classified into four  164 severity groups (i.e., mild, moderate, severe, and critical) based on symptoms as reported in the 165 previous study 38 . We found that patients with COVID-19 who had milder disease severity 166 showed significant higher Shannon diversity in their gut microbiome (Fig.3i) . Interestingly, the 167 composition of nrMAGs in patients with COVID-19 after recovery (negative for SARS-CoV-2 168 via RT-qPCR) were significantly different from Non-COVID-19 controls than from patients with 169 COVID-19 before recovery (positive for SARS-CoV-2 via RT-qPCR, Fig.3j . In line with a 170

previous study at the metabolic capacity level 39 , these results indicate that the gut microbiome of 171 patients with COVID-19 did not return to a relatively healthy status right after their recovery 172 from SARS-CoV-2 infection. We then observed that disease severity of COVID-19 was 173 significantly positively associated with the gut microbiome dissimilarity between COVID-19 174 patients and Non-COVID-19 controls (Fig.3k) . To understand the relation between disease 175 severity and short-term variation in the gut microbiome of patients with COVID-19, we traced 176 the changes in the microbiome within each individual associated with disease severity. 177

Interestingly, patients with COVID-19 who had milder disease severity showed lower temporal 178 variation in the gut microbiome (quantified by the Bray-Curtis dissimilarity of longitudinal 179 microbiome samples, Fig.3l ). The lower temporal variation of gut microbiome samples in milder 180 disease severity groups is partly due to the higher fraction of common nrMAGs across the 181 longitudinal microbiome samples in those groups (Fig.3m Identification of putative permissive and protective nrMAGs for COVID-19 severity 222

To further characterize the relation between the human gut microbiome and COVID-19, we 223 applied the generalized microbe-phenotype triangulation (GMPT) method to move beyond the 224 standard association analysis 44 (Fig.5a ). We first categorized participants into five different 225 disease severity groups (i.e., Non-COVID-19 healthy controls, mild, moderate, severe, and 226 critical) using data from Yeoh et al. 18 The differentially abundant nrMAGs were then calculated 227 using ANCOM 45 in the ten pairwise comparisons. Using this approach, all pairwise differential 228 abundance analyses yielded a total of 644 differentially abundant nrMAGs present in at least two 229 pair-wise comparisons. To understand the potential relationship between those candidate 230 nrMAGs with COVID-19, we then calculated the Spearman correlation coefficients between the 231 average relative abundances and COVID-19 severity score (e.g., Non-COVID-19 healthy 232 controls: 0; mild: 1; moderate: 2; severe: 3; and critical: 4) in different phenotype groups. Those 233 differentially abundant nrMAGs with positive (or negative) Spearman correlation coefficients are 234 potential permissive (protective) nrMAGs of COVID-19. Based on the frequency (≥ 6) of all 235 pairwise comparisons (n=10), we summarized the results from GMPT in Fig.5b and Table S1 . 236

This analysis identified a total of 74 nrMAGs that were associated with SARS-CoV-2 infection, 237

including 8 permissive (Spearman correlation > 0) nrMAGs, 63 protective (Spearman correlation 238 < 0) nrMAGs, and 3 neutral nrMAGs (Spearman correlation = 0). 239 240

We identified multiple species with highly similar genomes from those permissive nrMAGs 241 (Fig.5b) 

Here, we leveraged a total of 514 publicly available WMS sequenced samples from 6 SARS-287 COV-2 data sets and generated for the first time a high-quality COVID-19 related genome 288 catalog of the human microbiome. We recovered a large genome catalog representing 11,584 289

MAGs and 5,403 nrMAGs of the human microbiome. Through the construction of this microbial 290 genome catalog, we were able to provide the strain-level perspective to understanding the human 291 microbiome and COVID-19. 292 293

By interrogating the WMS sequencing data with different technical settings, we gained a more 294 comprehensive view of the microbial community associated with COVID-19. Due to the 295 inherent differences (e.g., age, diet, and genetic background) across the different data sets, our 296 goal was not targeted comparisons across data sets. Importantly, our study mainly focused on 297 two data sets (Zuo et al. 17 and Yeoh et al 18 .) with well-defined case and control subjects. 298

Although two nasopharyngeal microbiome data sets contained both patients with COVID-19 and 299

Non-COVID-19 controls, the statistical power was limited by the small sample size (Liu et al. 35 ) 300

and a large portion of sequencing reads from another data set (PRJNA743981 36 ) were from the 301 human host. Our analysis did not exclude these nasopharyngeal microbiome samples as they did 302 contribute unique high-quality MAGs to our nrMAGs collection. Furthermore, two gut 303 microbiome data sets (Britton et al. 53 and Cao et al. 54 ) without Non-COVID-19 controls served 304

as key resources of our MAGs collections. 305 306

Previous efforts have linked human microbiome diversity and COVID-19 11,14,33 . Coherently, the 307 human gut microbiome of patients with COVID-19 in our study exhibited decreased alpha 308 diversity at the nrMAGs level compared to the Non-COVID-19 healthy controls. Although we 309 did not found significant differences between patients with COVID-19 and Non-COVID-19 310 controls in two nasopharyngeal microbiome data sets, this may be due to the small sample size 311 and the fact that Non-COVID-19 controls are not health controls 35 . Notably, our analysis 312 identified that patients with COVID-19 after recovery (negative for SARS-CoV-2 via RT-qPCR) 313 differed more from Non-COVID-19 controls compared to patients with COVID-19 before 314

recovery. This finding supports the possibility that the gut microbiome of patients with COVID-315 19 may not return to a relatively healthy status right after their recovery from COVID-19 55 . 316

Given the fact that many patients recovering from SARS-CoV-2 infection have experienced 317

prolonged COVID-19 symptoms 56 , we hypothesize that long-lasting disease symptoms may be 318 associated with changes in the gut microbiome but this needs to be explored further. Our analysis 319 also supports the main findings from the original study of Yeoh et al 18 . That the gut microbiota 320 composition reflects disease severity. Specifically, we revealed this connection through the Bray-321

Curtis dissimilarity comparison between severity group and healthy controls, and changes in 322 microbial community membership longitudinally overtime at the nrMAGs level. Interestingly, 323 the connection between disease severity of COVID-19 and the gut microbiome has also been 324

reported at both the species-and metabolic capacity-level by a recent study 39 . 325 326

Using machine learning models, we demonstrated that the gut microbiome signatures at the 327 nrMAG-level can accurately detected COVID-19 from healthy controls. In particular, host gut microbiota provides colonization resistance against pathogens, for example, 347 a previous study reported that mice treated with neomycin antibiotics were more susceptible than 348 control mice to influenza viruses 63 . And it turned out that neomycin-sensitive bacteria naturally 349 present in the mice's bodies provided a trigger that led to the production of T cells and antibodies 350 that could fight an influenza infection in the lungs. Notably, our study identified a set of COVID-351

19 related nrMAGs and their determinants (i.e., permissive, and protective) potentially involved 352 in disease pathogenesis. It is important to note that these protective bacteria have also been 353 reported to be related to SARS-CoV-2 infection. For example, the host immunity symbionts 354 beneficial bacterial species B. obeum was identified to be depleted in patients with COVID-19 in 355 multiple studies 11,17 . F. prausnitzii, an anti-inflammatory and butyric acid-producing commensal 356 bacterium, was found to be underrepresented in patients with COVID-19 17,18,64 . Moreover, our 357 analysis enables the direct microbial genome comparison between permissive and protective 358 nrMAGs. Consistent with previous reports of a relationship of the pentose phosphate pathway 359

and SARS-CoV-2 infection 50-52 , our findings support that overrepresentation of permissive 360 1 0 nrMAGs and underrepresentation of protective nrMAGs may upregulate the pentose phosphate 361 pathway as their genome are shown to be highly intact in those relevant modules. In contrast, the 362 pentose phosphate pathway related KEGG modules showed significant lower module 363 completeness in genomes of protective nrMAGs. Together, these results provide valuable 364 insights into the mechanisms underlying host-microbiome interaction and COVID-19 severity 365

and progression, and most importantly, future work may then be able to capture molecular 366 mechanisms of these specific strains more easily in the severity of SARS-CoV-2 infection. 367 368

The current study has several limitations. First, although we included a large number of shotgun 369 metagenomic sequencing samples from the COVID-19 related human microbiome study 370

(publicly available as of August 2021), most of the microbiome samples came from China. This 371 limitation could be addressed by following this work with collection of more human microbiome 372 samples from different populations and body sites to construct a more comprehensive genome 373 catalog to reveal the full landscape of the human microbiome in COVID-19. Second, even 374 though we adjusted for some potential confounders in our statistical models, we were unable to 375 assess some covariates such as: medication, diet, and psychological stress that are not publicly 376

available. Third, consistent with multiple MAG-related WMS studies 25,65,66 , we only recovered 377

MAGs from bacteria and archaea. Given the fact that de novo discovery of non-bacterial 378 genomes is quite challenging 67 , future study targets for other domains, including fungi and 379 viruses, will give a more comprehensive view in the context of host-specific microbiotas and 380 COVID-19. Although the majority of MAGs we reconstructed in this study have high quality, 381 future investigations aiming for recovering the complete genome of microbes will further 382 enhance our understanding of the interaction between human microbiome and SARS-CoV-2 383 infection 68,69 . Finally, additional experiments are needed to assess the casual role of candidate 384 permissive and protective nrMAGs in COVID-19 progression. Nevertheless, given the large 385 uncultured diversity still remaining in the human gut microbiome and deficiency of both 386 annotated genes and reference genomes, having a high-quality genome catalog substantially 387 enhances the resolution and accuracy of metagenome-based COVID-19 studies. Therefore, the 388 presented genome catalog represents a key step toward mechanistic understanding the role of the 389 human gut microbiome in SARS-CoV-2 infection. 390 391

In summary, we present here the first construction of the genome catalog using assembly and 392 reference free binning of metagenome in patients with COVID-19 and Non-COVID-19 controls. 393

Our findings support the close connection between SARS-CoV-2 infection and the human gut 394 microbiome. These insights into metagenomic strain-level aspects of relation in human 395 microbiome and COVID-19 and genome context will form the basis of future studies. 396 397 398 399 400 

Data collection 441 We identified COVID-19 metagenomic sequencing studies from keyword searches in PubMed 442

and online repositories (i.e., NCBI, ENA, and GSA) and by following references in meta-443

analyses and related microbiome studies. We included samples with publicly available raw 444

shotgun metagenomic sequencing data (paired fastq files) and metadata indicating patients with 445

COVID-19 or Non-COVID-19 control status. All the sequencing data were downloaded from 446 online repositories or links provided in the original publications, but some metadata were 447 acquired after personal communication with the authors. We did not include any studies which 448 required additional ethics committee approvals or authorizations for access. A total of 514 449 microbiome samples from six public microbiome data sets were analyzed in this study ( Statistical analysis 500

Microbial alpha and beta diversity measures were calculated at the nrMAGs level using vegan 501 package (v2.5.7) in R. Principal coordinates analysis (PcoA) plots were generated with Bray-502

Curtis dissimilarity. Differences in microbiome compositions across different groups were tested 503 by the permutational multivariate analysis of variance (PERMANOVA) using the "adonis" 504 function in R's vegan package. All PERMANOVA tests were performed with 9999 permutations 505 based on Bray-Curtis dissimilarity. Differences between groups were analyzed using a 506

Wilcoxon-Mann-Whitney test. For differential abundance analysis in GMPT (Generalized 507

Microbe Phenotype Triangulation) pipeline 44 , we used ANCOM (analysis of composition of 508 microbiomes) 45 , with a Benjamini-Hochberg correction at 5% level of significance, and adjusted 509 each patient's identifier as a random effect. Only the nrMAGs that were presented in at least 5% 510 of samples were included. learning process was conducted using features of nrMAGs with 5-fold cross validation. The data 517 was split into a training set and a test set, with 80% of the data forming the training data and the 518 remaining 20% forming the test set. And then we randomly split the data 50 times. The 519

performance of the classification model was evaluated using AUROC (area under the receiver 520 operating characteristic curve) and AUPRC (area under the precision-recall curve) on the test set. 521

The importance of each feature was quantified by the Mean Decrease in Accuracy (MDA) of the 522 classifier due to the exclusion (or permutation) of this feature. The more the accuracy of the 523 classifier decreases due to the exclusion (or permutation) of a single feature, the more important 524 that feature is deemed for classification of the data. We then built Random Forest regression 525 model with 5-fold cross-validation to predict the exact date of microbiome sample collected 526 before or after negative RT-qPCR result. We randomly split the data 50 times. The importance of 527 each feature in the regression was quantified by percent increase in mean square error. Pearson 528 correlation coefficient between the true and predicted date of negative RT-qPCR result was used 529

to evaluate the performance. All statistical analysis was performed with R (version 3.6.3). 530 531

Data availability 532

All data used in this article come from publicly available sources. e  m  a  n  n  ,  T  .  P  r  o  k  k  a  :  r  a  p  i  d  p  r  o  k  a  r  y  o  t  i  c  g  e  n  o  m  e  a  n  n  o  t  a  t  i  o  n  .  B  i  o  i  n  f  o  r  m  a  t  i  c  s   3  0   ,  2  0  6  8  -686   2  0  6  9  ,  d  o  i  :  1  0  .  1  0  9  3  /  b  i  o  i  n  f  o  r  m  a  t  i  c  s  /  b  t  u  1  5  3  (  2  0  1  4 ) . 4  9  R  u  i  z  -P  e  r  e  z  ,  C  .  A  .  ,  C  o  n  r  a  d  ,  R  .  E  .  &  K  o  n  s  t  a  n  t  i  n  i  d  i  s  ,  K  .  T  .  M  i  c  r  o  b  e  A  n  n  o  t  a  t  o  r  :  a  u  s  e  r  -f  r  i  e  n  d  l  y  ,   688   c  o  m  p  r  e  h  e  n  s  i  v  e  f  u  n  c  t  i  o  n  a  l  a  n  n  o  t  a  t  i  o  n  p  i  p  e  l  i  n  e  f  o  r  m  i  c  r  o  b  i  a  l  g  e  n  o  m  e x  p  a  n  d  e  d  c  a  t  a  l  o  g  o  f  m  i  c  r  o  b  i  a  l  g  e  n  e  s  a  n  d  m  e  t  a  g  e  n  o  m  e  -a  s  s  e  m  b  l  e  d   729   g  e  n  o  m  e  s  f  r  o  m  t  h  e  p  i  g  g  u  t  m  i  c  r  o  b  i  o  m  e  .  N  a  t  C  o  m  m  u  n   1  2   ,  1  1  0  6  ,  d  o  i  :  1  0  .  1  0  3  8  /  s  4  1  4  6  7  -0  2  1  -730   2  1  2  9  5  -0  (  2  0  2  1  )  .   731   6  6  L  e  v  i  n  ,  D  .  e  t  a  l  .  D  i  v  e  r  s  i  t  y  a  n  d  f  u  n  c  t  i  o  n  a  l  l  a  n  d  s  c  a  p  e  s  i  n  t  h  e  m  i  c  r  o  b  i  o  t  a  o  f  a  n  i  m  a  l  s  i  n  t Phylogenetic tree of nrMAGs constructed using PhyloPhlAn. The color of outer cycle and clades 900

represents phylum and bar plot within cycle represents the average relative abundance across all 901 microbiome samples. represents the source of the microbiome samples from the human gut (light red) or nasopharynx 916 (light green). i, Shannon diversity at different disease severity groups. j, Boxplot of the gut 917 microbiome Bray-Curtis dissimilarity between healthy controls and patients with COVID-19 918 before or after their nasopharyngeal aspirates or swabs tested negative for SARS-CoV-2 via RT-919 qPCR. k, Boxplot of the gut microbiome Bray-Curtis dissimilarity between healthy controls and 920 patients with COVID-19 from different disease severity groups. l, Boxplot of Bray-Curtis 921 dissimilarity of individual microbiome temporal changes over time from different disease 922

The fraction of common nrMAGs on patients with COVID-19 over time. P 923 values were calculated by two-sided Wilcoxon-Mann-Whitney test

The nrMAG-based machine learning model predict the progression of COVID-19

Pearson correlation coefficient between the true and predicted date of negative RT-qPCR result 930 on the random forest regression models. b, The top 30 important nrMAGs related to performance 931 of prediction. The importance of each feature in the regression was quantified by percent 932 increase in mean square error (%IncMSE). The length of horizontal bar represents the 933 mean %IncMSE value. The colors of vertical bar represent the taxonomy information of 934 nrMAGs at the family level

Genome annotation of permissive and protective nrMAGs of COVID-19. a, Principal 1004 Component Analysis (PCA) plot of KEGG module completeness from all genomes of permissive 1005 and protective nrMAGs. b, The top 20 differential KEGG modules between permissive and 1006 protective nrMAGs ranked based on the mean difference

severity. Differential abundance analysis was carried out on each possible pairwise comparison 965(10 pair wise comparisons among 5 groups). The differentially abundant nrMAGs pool were 966 originated from these pairwise analyses. The differentially abundant nrMAGs were ranked based 967 on their frequency appearing in all the pairwise comparisons and differentiability (descending 968 order). We further used the average relative abundance of nrMAGs and the disease severity to 969 calculate the Spearman correlation coefficient. Here positive (negative) Spearman correlation 970 coefficient (ρ) represent the permissive (protective) nrMAGs of COVID-19 severity. And the 971 spearman correlation with 0 means the nrMAGs may be neutral to the severity of SARS-CoV-2 972infection. b, The heat map showed the abundance distribution of permissive, neutral, and 973protective nrMAGs across different disease severity groups identified using GMPT. These 974 nrMAGs were taxonomically annotated using GTDB-Tk based on the Genome Taxonomy  975 Database. The colors of the taxonomical label represent permissive, protective, or neutral 976 nrMAGs. The phylogenetic tree of these nrMAGs was constructed using PhyloPhlAn .  977  978  979  980  981  982  983  984  985  986  987  988  989  990  991  992  993  994  995  996  997  998  999  1000  1001